Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients

European Respiratory Journal

Volumn 23, Issue 1, 2004, Pages 98-102

  Marchac, V ^a   Equi, A ^b   Le Bihan Benjamin, C ^a   Hodson, M ^b   Bush, A ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspergillus fumigatus; Cystic fibrosis; Stenotrophomonas maltophilia

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; STEROID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIUM ISOLATION; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; INFANT; INFECTION RISK; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; NONHUMAN; NUTRITIONAL HEALTH; OUTCOMES RESEARCH; PATHOGENESIS; PERSISTENT INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SPUTUM ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; STEROID THERAPY;

ADULT; ANTI-BACTERIAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE-CONTROL STUDIES; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; SPUTUM; STENOTROPHOMONAS MALTOPHILIA; STEROIDS;

EID: 0347136002     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00007203     Document Type: Article

References (11)

1. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46: 881-885.
2. Huang NN, VanLoon EL, Sheng KT. The flora of the respiratory tract of patients with cystic fibrosis of the pancreas. J Pediatr 1961; 59: 512-521.
3. Cystic Fibrosis Foundation. Patient Registry 1996. Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 1997.
4. Valerius NH, Koch C, Hoiby NM. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725-726.
5. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335.
6. Blessing J, Walker J, Maybury B, et al. Pseudomonas cepacia and Pseudomonas maltophilia in the cystic fibrosis patient. Am Rev Respir Dis 1979; 119: 262.
7. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998; 25: 304-308.
8. Karpati F, Malborg AS, Alfredsson H, et al. Bacterial colonisation with Xanthomonas maltophilia - a retrospective study in a cystic fibrosis patient population. Infection 1994; 22: 258-263.
9. Huet FE, Piegay C, Aho S, Neuwirth C, Bellon G. Risk factors of colonization and/or infection by Stenotrophomonas maltophilia in cystic fibrosis patients. Pediatr Pulmonol 1999; 19: 275.
10. Rosenstein BJ, Cutting GR, for the Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132: 589-595.
11. Talmaciu I, Varlotaa L, Mortensen J, et al. Bacterial colonization with Xanthommonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000; 30: 10-15.